Dapirolizumab
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus[1].
Product Specifications
CAS Number
1416147-64-2
UNSPSC
12352203
Target
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/dapirolizumab.html
Purity
99.66
Smiles
[Dapirolizumab]
Molecular Weight
(145.5 kDa)
References & Citations
[1]Furie RA, et al., Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford) . 2021 Nov 3;60 (11) :5397-5407.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AP54516PU-N 400 µL
VPS45A (VPS45) (C-term) Rabbit Polyclonal Antibody
Sign In for Pricing
View Details 
TP310892L 1 mg
PPPDE2 (DESI1) (NM_015704) Human Recombinant Protein
Sign In for Pricing
View Details 
